Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to -$10.6 million.

  • Aytu Biopharma's Income from Continuing Operations fell 165190.62% to -$10.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$24.8 million, marking a year-over-year decrease of 53670.01%. This contributed to the annual value of -$14.4 million for FY2025, which is 1499.2% down from last year.
  • Aytu Biopharma's Income from Continuing Operations amounted to -$10.6 million in Q4 2025, which was down 165190.62% from $2.0 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Income from Continuing Operations high stood at $3.9 million for Q1 2025, and its period low was -$53.3 million during Q1 2022.
  • For the 5-year period, Aytu Biopharma's Income from Continuing Operations averaged around -$10.3 million, with its median value being -$6.9 million (2022).
  • Within the past 5 years, the most significant YoY rise in Aytu Biopharma's Income from Continuing Operations was 27220.28% (2025), while the steepest drop was 165190.62% (2025).
  • Quarter analysis of 5 years shows Aytu Biopharma's Income from Continuing Operations stood at -$11.5 million in 2021, then skyrocketed by 42.04% to -$6.7 million in 2022, then surged by 108.95% to $599000.0 in 2023, then rose by 13.86% to $682000.0 in 2024, then crashed by 1651.91% to -$10.6 million in 2025.
  • Its last three reported values are -$10.6 million in Q4 2025, $2.0 million for Q3 2025, and -$20.1 million during Q2 2025.